

Yang Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4419689/publications.pdf>

Version: 2024-02-01

48
papers

2,147
citations

516215

16
h-index

301761

39
g-index

50
all docs

50
docs citations

50
times ranked

4186
citing authors

#	ARTICLE	IF	CITATIONS
1	Dissection of mechanisms of Chinese medicinal formula Realgar- <i>Indigo naturalis</i> as an effective treatment for promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4826-4831.	3.3	688
2	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell, 2015, 27, 617-630.	7.7	449
3	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia, 2020, 34, 1503-1511.	3.3	208
4	C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2450-2455.	3.3	118
5	Targeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein. Science Translational Medicine, 2012, 4, 127ra38.	5.8	76
6	SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia, 2018, 32, 2659-2671.	3.3	68
7	A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. Annals of Translational Medicine, 2020, 8, 481-481.	0.7	64
8	JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia, 2021, 35, 2616-2620.	3.3	63
9	NK/T-cell lymphomas. Leukemia, 2021, 35, 2460-2468.	3.3	55
10	High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. Journal of Cancer, 2019, 10, 3239-3245.	1.2	49
11	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood, 2020, 136, 1477-1486.	0.6	43
12	The Role of the HOXA Gene Family in Acute Myeloid Leukemia. Genes, 2019, 10, 621.	1.0	40
13	Synergistic Antitumor Effect and Mechanism of Chidamide Combined with Gemcitabine, Oxaliplatin or Zanubrutinib in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 14-15.	0.6	28
14	Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. Blood, 2020, 136, 50-51.	0.6	18
15	Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). Leukemia, 2021, 35, 1661-1670.	3.3	17
16	An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy. Clinical Cancer Research, 2021, 27, 255-266.	3.2	17
17	Arsenic Trioxide Induces Apoptosis of Burkitt Lymphoma Cell Lines Through Multiple Apoptotic Pathways and Triggers Antiangiogenesis. Oncology Research, 2011, 19, 149-163.	0.6	16
18	A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. Leukemia, 2021, 35, 3212-3222.	3.3	15

#	ARTICLE	IF	CITATIONS
19	Changing causes of death in persons with haematological cancers 1975–2016. <i>Leukemia</i> , 2022, 36, 1850-1860.	3.3	12
20	Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 540.	1.3	10
21	A predictive score for progression of COVID-19 in hospitalized persons: a cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 33.	1.1	9
22	Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i> -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). <i>Blood</i> , 2021, 138, 3598-3598.	0.6	9
23	Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based <i>SCMC</i> <i>ALL</i> 2005 protocol. <i>British Journal of Haematology</i> , 2015, 169, 267-277.	1.2	8
24	DNA crosslinking and recombination-activating genes 1/2 (<i>RAG1/2</i>) are required for oncogenic splicing in acute lymphoblastic leukemia. <i>Cancer Communications</i> , 2021, 41, 1116-1136.	3.7	7
25	Drug resistance biomarker <i>ABCC4</i> of selinexor and immune feature in multiple myeloma. <i>International Immunopharmacology</i> , 2022, 108, 108722.	1.7	7
26	A Practical Strategy of Monitoring Minimal Residue Disease and Intervention for Central Nervous System Relapse of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 388-393.	0.3	6
27	Effects of Alternative Splicing Events on Acute Myeloid Leukemia. <i>DNA and Cell Biology</i> , 2020, 39, 2040-2051.	0.9	6
28	Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6373-6384.	1.6	6
29	Multifunctional DNA mediated spatially confined assembly for antibody orientation: Surpassing sensitivity and accuracy for rituximab detection. <i>Chemical Engineering Journal</i> , 2021, 419, 129613.	6.6	6
30	Prognosis and regulation of an adenylyl cyclase network in acute myeloid leukemia. <i>Aging</i> , 2020, 12, 11864-11877.	1.4	5
31	A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience. <i>Cancer Research and Treatment</i> , 2020, 52, 573-585.	1.3	5
32	Toward the Cure of Acute Lymphoblastic Leukemia in Children in China. <i>JCO Global Oncology</i> , 2021, 7, 1176-1186.	0.8	4
33	Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models. <i>Leukemia</i> , 2021, 35, 3073-3077.	3.3	4
34	Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. <i>International Journal of Hematology</i> , 2019, 110, 458-465.	0.7	2
35	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 8831-8839.	0.9	2
36	Bone Marrow Adipocyte Shapes Metabolism and Immunity in Tumor Microenvironment to Promote Multiple Myeloma. <i>Blood</i> , 2021, 138, 892-892.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma. <i>Blood</i> , 2021, 138, 459-459.	0.6	2
38	Adipocyte Fatty Acid Binding Protein Promotes Multiple Myeloma through Regulating Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
39	An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 33-34.	0.6	1
40	Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
41	Inflammation-based Glasgow prognostic score as an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. <i>Chinese Medical Journal</i> , 2021, 134, 579-581.	0.9	0
42	Integrative Genome-Wide Analysis of RNA Binding and Splicing Reveals Complex Loss and Gain of Function Alterations By SRSF2 P95 Mutations in Myelodysplasia. <i>Blood</i> , 2015, 126, 141-141.	0.6	0
43	Stemness Signature Predicts Outcomes and Identifies Candidates for Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1329-1329.	0.6	0
44	Bone Marrow Adipocyte Promotes Epithelial-Mesenchymal-Transition-like Activation in Multiple Myeloma Via CXCL-12/CXCR4 Axis. <i>Blood</i> , 2021, 138, 1584-1584.	0.6	0
45	Systematic Construction of an Autophagic Risk Model in Bone Marrow for Prognostic Prediction in Multiple Myeloma. <i>Blood</i> , 2021, 138, 4713-4713.	0.6	0
46	An Immune Score Model of the Bone Marrow Micro-Environment Predicts Survival in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2020, 136, 38-38.	0.6	0
47	An Accurate Prognostic Survival Model of Survival Based on Expression of Genes Involved in Plasma Cell Metabolism. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
48	Clinical Investigation and Biological Mechanism of Tigecycline on Coagulation Disorders in Cancer Patients. <i>Blood</i> , 2020, 136, 25-25.	0.6	0